Influences of sleep and the circadian rhythm on iron-status indices

Ridefelt, Peter; Larsson, Anders; Rehman, Javaid-ur; Axelsson, John

doi:10.1016/j.clinbiochem.2010.08.023

Cited by 35 publications

(17 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data are not in full agreement with previous studies, e.g., we and others previously found that TS decreases during a day of a regular diet, especially after noon (4,20 ). These inconsistencies between studies in the variation in daily TS may be due to relatively small sample sizes, and differences in time of blood sampling and diet.…”

Section: Discussioncontrasting

confidence: 56%

Diurnal Rhythm rather than Dietary Iron Mediates Daily Hepcidin Variations

Schaap¹,

Hendriks

Kortman³

et al. 2013

Clinical Chemistry

View full text Add to dashboard Cite

BACKGROUND:The iron-regulating hormone hepcidin is a promising biomarker in the diagnosis of iron disorders. Concentrations of hepcidin have been shown to increase during the day in individuals who are following a regular diet. It is currently unknown whether these increases are determined by an innate rhythm or by other factors. We aimed to assess the effect of dietary iron on hepcidin concentrations during the day.

show abstract

Section: Discussioncontrasting

confidence: 56%

Diurnal Rhythm rather than Dietary Iron Mediates Daily Hepcidin Variations

Schaap¹,

Hendriks

Kortman³

et al. 2013

Clinical Chemistry

View full text Add to dashboard Cite

show abstract

“…ARNTL , and its product BMAL1, is mainly known for interactions with CLOCK genes and generation of circadian rhythm. Notably, serum iron 16, 36 , liver iron 37 , hepcidin 38 , and TfR1 gene expression 39 all show circadian variation. The region affecting transferrin on chromosome 8 contains the NAT2 gene, which again has no obvious relevance for iron.…”

Section: Discussionmentioning

confidence: 99%

Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis

Benyamin¹,

Esko²,

Ried³

et al. 2014

Nat Commun

239

251

View full text Add to dashboard Cite

Variation in body iron is associated with or causes diseases, including anaemia and iron overload. Here we analyse genetic association data on biochemical markers of iron status from eleven European-population studies, with replication in eight additional cohorts (total up to 48,972 subjects). We find eleven genome-wide-significant (p < 5 × 10−8) loci, some including known iron-related genes (HFE, SLC40A1, TF, TFR2, TFRC, TMPRSS6) and others novel (ABO, ARNTL, FADS2, NAT2, TEX14). SNPs at ARNTL, TF, and TFR2 affect iron markers in HFE C282Y homozygotes at risk for hemochromatosis. There is substantial overlap between our iron loci and loci affecting erythrocyte and lipid phenotypes. These results will facilitate investigation of the roles of iron in disease.

show abstract

“…The findings of the TREAT study not only underlined possible risk of ESA therapy when aiming at complete anemia correction, but also showed that iron therapy can increase Hb levels and stabilize anemia delaying the start of ESA therapy (at least in the ND-CKD population). 20 Similarly, Stancu et al 17,21 showed that some patients with adequate intra-marrow iron stores can obtain an increase of Hb levels following IV iron administration.…”

Section: Indications To Iron Therapymentioning

confidence: 98%

“…In particular, they are affected by malnutrition and inflammation, which are both frequently observed in CKD patients. Moreover, they have diurnal variations; in dialysis patients, the timing of blood collection may then influence obtained data. However, they are cheap and easy to measure.…”

Section: How To Define Iron Deficiency or Excess: Serum Markersmentioning

confidence: 99%

Clinical practice guidelines on iron therapy: A critical evaluation

Vecchio

Locatelli

2017

Hemodialysis International

View full text Add to dashboard Cite

Anemia is common among patients with chronic kidney disease (CKD) and it is managed primarily with erythropoiesis-stimulating agents (ESA) and iron therapy. Following concerns around ESA therapy and economic constraints, IV iron is more and more administered worldwide.Several guidelines or position papers, which give indications on iron therapy in CKD patients, have been issued in Nephrology. Unfortunately, the field is characterized by a lack of evidence. As a result, the recommendations/suggestions are not uniform.There is general consensus to prescribe iron therapy to patients who are clearly iron deficient. In addition, iron therapy may increase Hb values, delay the start of ESA therapy in ESA-na€ ıve patients and reduce ESA dose in ESA-treated patients. However, there is debate on the safety and efficacy of IV iron therapy when given in the presence of already high serum ferritin levels. In addition, not all the guidelines/position papers differentiate between non-dialysis/dialysis patients and between the presence/absence of ESA therapy. Many international Bodies or Societies suggest caution when administering IV iron during infections. A trial of oral iron should be considered as a first step, especially in the ND-CKD population. Finally, recommendations on the prevention of anaphylactic reactions following IV iron therapy are given by several bodies. There is consensus that IV iron is to be administered in the presence of resuscitative facilities (including medications) and personnel trained for emergencies.

show abstract

Influences of sleep and the circadian rhythm on iron-status indices

Cited by 35 publications

References 32 publications

Diurnal Rhythm rather than Dietary Iron Mediates Daily Hepcidin Variations

Diurnal Rhythm rather than Dietary Iron Mediates Daily Hepcidin Variations

Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis

Clinical practice guidelines on iron therapy: A critical evaluation

Contact Info

Product

Resources

About